ALLMedicine™ Hypogammaglobulinemia Center

Jun 29th, 2022 - Disorders of the long arm of chromosome 11 (11q) are rare and involve various chromosomal regions. Patients with 11q disorders, including Jacobsen syndrome, often present with a susceptibility for bacterial and prolonged viral and fungal infection...

Jun 25th, 2022 - Hypogammaglobulinemia is a major adverse effect from rituximab. However, the association between rituximab-induced hypogammaglobulinemia and infection frequency is unknown. Patients who received rituximab for complicated nephrotic syndrome between...

Jun 25th, 2022 - Severe combined immunodeficiency (SCID) is characterized by severe, early-onset infection in infants. B-cell lymphoma/leukemia (BCL) 10 defects causing SCID have been reported previously in two patients. A seven-month-old female infant was admitte...

Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Jun 24th, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...

Jun 24th, 2022 - Background: With the availability of whole exome sequencing (WES) and whole genome sequencing (WGS) for patients with suspected primary immune deficiency or Primary Immune Regulatory Disorder (PIRD), the number of recognized PID s and PIRD s has i...

Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

May 3rd, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...

Mar 3rd, 2022 - The number of monoclonal antibodies developed for therapeutic use has rapidly expanded over the last decade due to their generally favorable adverse effect (AE) profiles and efficacy. 1 Tumor necrosis factor α inhibitors and general integrin antago.

Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...

Jan 21st, 2022 - The China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) as a treatment for adult patients with Waldenström macroglobulinemia.1 The application is supported by...

Dec 29th, 2021 - A biologics license application seeking the approval of the off-the-shelf, T-cell redirecting bispecific antibody, teclistamab (JNJ-64007957), for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.1 The ap...

Oct 6th, 2021 - Brad S. Kahl, MD Optimizing treatment for patients with indolent non-Hodgkin lymphoma (iNHL) has become a challenge as the frontline and recurrent treatment settings continue to evolve, said Brad S. Kahl, MD. "The management of [recurrent] indol...